The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.
about
Lymphocyte-activation gene-3, an important immune checkpoint in cancerBeyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint RegulatorsThe immunological synapse: the gateway to the HIV reservoirLAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathwayLymphocyte activation gene 3 and coronary artery diseaseLymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral loadThe negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer modelLAG-3 in Cancer Immunotherapy.Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target.Emerging immune checkpoints for cancer therapy.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.LAG3 (CD223) as a cancer immunotherapy target.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.Cloning of rat lymphocyte activation gene-3 (Lag3; CD223) cDNA and its mRNA expression in rat tissues.Control of NK Cell Activation by Immune Checkpoint Molecules.CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression
P2860
Q26746209-E3D32A76-18E4-428C-B4B6-7452A73067ABQ26782799-9A8D03ED-8DDB-4634-8D5D-2E469308BCBDQ27002959-62B9227D-31B0-4958-9984-6BDF32EC02F9Q28190955-61E32361-3B50-4F7F-A203-6CAB755DB16FQ30275618-7D62C7B5-CA82-48B0-BA3E-6716EB855154Q34381879-36EDB28A-CA54-48CF-ADD5-FAAB967B86C5Q34417483-5C139571-3D86-46B5-85D1-B225B2FD0A55Q36413772-CE3D9929-A63A-4DEB-AE16-18518139BF56Q36416383-55723EC2-5618-46FE-8E47-F87586E77A17Q37536649-661011AD-0144-4082-8B84-06EC123C9B28Q37766241-8CAE61FA-674F-46E2-8729-AD9BCC8C5CA9Q38584979-623CF4B1-1D2C-40F1-8533-CE35F0826CE8Q38636569-781FABE0-7B39-41D9-B221-011E6C0C183EQ39078341-370426C0-D3F4-42B4-AF43-C835A7714F4DQ39160974-B725D91C-8224-4958-8DEA-D3B7314D02C1Q39313794-74CF7224-AB78-44F8-BD99-BC956DE98075Q39748865-FEDFB83A-6D6F-41E4-AC7D-3606C9D2578DQ42621751-E9263167-68B5-48A0-938A-43202063F22DQ47128718-026E104F-D1D8-43EA-A271-9F94BD3C9542Q50030507-82907C39-DA8F-4BAB-85DD-1D2D4E3F3438Q57050465-24D69242-BA46-46B2-8D55-F03193048208
P2860
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The MHC class II ligand lympho ...... peptide-MHC class I complexes.
@ast
The MHC class II ligand lympho ...... peptide-MHC class I complexes.
@en
type
label
The MHC class II ligand lympho ...... peptide-MHC class I complexes.
@ast
The MHC class II ligand lympho ...... peptide-MHC class I complexes.
@en
prefLabel
The MHC class II ligand lympho ...... peptide-MHC class I complexes.
@ast
The MHC class II ligand lympho ...... peptide-MHC class I complexes.
@en
P2860
P356
P1476
The MHC class II ligand lympho ...... peptide-MHC class I complexes.
@en
P2093
P2860
P304
P356
10.1093/INTIMM/11.11.1745
P577
1999-11-01T00:00:00Z